Uncategorized
Severity of corneal neovascularization may be reduced with topical ranibizumab
Corneal neovascularization may be treated with topical ranibizumab to reduce severity through decrease in the vessel caliber, according to a study. The prospective, open-label, monocentric, uncontrolled, noncomparative study included 10 eyes of nine patients with corneal neovascularization. Lucentis (ranibizumab 1%, Genentech) was administered 4 times a day for 3 weeks with a follow-up of 16 weeks. Measurements were taken for neovascular area, vessel caliber, area occupied by the corneal neovessels, mean diameter of the corneal neovessels and invasion area.